There has been a shortage of HLA-identical siblings or unrelated donors for Chinese patients who need HSCT. Prof. Huang and his team at Peking University pioneered a systemic study of haploidentical blood and marrow transplantation without in vitro T-cell depletion, which gradually developed to a haplo system, known as Beijing Protocol. Beijing Protocol Haplo HSCT can achieve comparable outcomes and quality of life with HLA identical sibling and HLA Matched unrelated donor transplantation - Compared to EBMT database. Haplo-HSCT is also superior to chemotherapy and cord blood HSCT. Since Beijing Protocol has been widely incorporated into clinical practice in most comprehensive HSCT centers in China N 90, since 2013 Haplo HSCT has become the largest donor source compared with ISD donors and now take nearly 51% of total allo HSCT cases in China. Beijing Protocol was replicated and conducted with promising results by Di Bartolomeo et al. in Italy and Israel, as well as in France, Korea, Japan and other 10 countries. As R. Handgretinger commented in Blood 2014, “more than half of the HLA haplotype mismatched transplantations performed worldwide will follow Beijing Protocol.